Neuromyelitis Optica Treatments

Find Neuromyelitis Optica Treatments

Brand Name

Ultomiris

Generic Name

Ravulizumab

View Brand Information

FDA approval date: December 21, 2018

Classification: Complement Inhibitor

Form: Solution

What is Ultomiris (Ravulizumab)?

ULTOMIRIS is indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria . the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy . ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria . the treatment of adults and pediatric patients one month of age and older with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy . Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome . Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome .

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

A Single Arm Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Control of Intravascular Hemolysis on Currently Available C5 Inhibitor Therapy

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: This study is researching a treatment combination with two experimental drugs called pozelimab and cemdisiran referred to as study drugs. Researchers are looking for a better way to treat Paroxysmal Nocturnal Hemoglobinuria (PNH). The aim of the study is to see how well the pozelimab and cemdisiran combination works to lower hemolysis in participants whose PNH has been not well controlled even aft...

A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The primary objective of this study is to demonstrate the efficacy of ravulizumab vs placebo in reducing the severity of DGF as measured by time to freedom from dialysis in adult participants who are at high risk of DGF after undergoing transplant of deceased donor kidney.

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug

Summary: The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

View All Clinical Trials

Related Latest Advances

Ravulizumab administration for relapse prevention in atypical hemolytic uremic syndrome with a CFH variant: A case report.

Journal: Internal medicine (Tokyo, Japan)

Published: June 10, 2026

Complement C5 inhibitor crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria.

Journal: Expert review of clinical pharmacology

Published: May 29, 2026

Biologics in Kidney Transplantation: Why and How Should We Personalize Their Dosage?

Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

Published: May 25, 2026

View All Latest Advances